Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical has received regulatory approval from China’s National Medical Products Administration for a supplementary drug application related to its Potassium Chloride Granules, specifically approving a change in the product’s marketing licence holder. The approval confirms the product meets national drug registration requirements and formalizes the transfer of all marketing authorization holder rights, including manufacturing and commercialization, from Guangzhou Aige Biotechnology to Xinhua Pharmaceutical under a previously signed technology and holder transfer contract.
The completed transfer consolidates ownership and control of Potassium Chloride Granules under Xinhua Pharmaceutical, enabling the company to directly manage production, sales and marketing of this prescription product. This move is expected to strengthen Xinhua Pharmaceutical’s product portfolio and operational autonomy in the Chinese prescription drug market, while providing greater clarity for partners and other stakeholders over regulatory responsibilities for the therapy.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer engaged in the development, production and sale of prescription drugs and related formulations. The company focuses on supplying generic and specialized medicines to the domestic healthcare market and operates as a marketing authorization holder for multiple products.
Average Trading Volume: 913,162
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.49B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.